Ultra SermorLean

Ultra SermorLean is a program combining three prescription components: Sermorelin, Low Dose Naltrexone (LDN), and Ultra Lipotropic 10 injectable. Each component has been studied individually in clinical and research contexts. Whether this program is appropriate for you is a determination made solely by your independent licensed healthcare provider following a thorough clinical evaluation, including required blood testing.

About the Components:

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied in published research for its effects on growth hormone secretion. Sermorelin is a prescription medication and is not FDA-approved for weight management indications. Its use in this program is off-label and at the sole discretion of your prescribing provider.

Low Dose Naltrexone (LDN) refers to the use of naltrexone at doses significantly lower than those used for its FDA-approved indications (alcohol and opioid use disorder). At low doses, naltrexone has been studied for a range of off-label applications in published research. All use of LDN in this program is off-label and at the sole discretion of your prescribing provider. Important: LDN is absolutely contraindicated in patients currently using opioid medications. Discuss all current medications with your provider before starting.

Ultra Lipotropic 10 is a compounded injectable preparation containing Methionine, Inositol, Choline, L-Carnitine, and B vitamins. These compounds play roles in normal metabolic processes and liver function as documented in the nutritional and clinical literature.

Potential Uses - as determined by your independent licensed healthcare provider:

– Components of this program may be prescribed as part of a comprehensive provider-directed wellness plan.
– Whether any component is appropriate for your individual health goals is determined solely by your independent licensed provider following clinical evaluation and blood testing.

These are not established indications for these compounded formulations. All uses described are off-label. Individual results vary significantly and are not guaranteed.

Monthly Program Includes:
– 9 mg vial of Sermorelin
– 30-day supply of Low Dose Naltrexone capsules
– 10 mL vial of Ultra Lipotropic 10

Three-Month Program Includes:
– Three 9mg vials of Sermorelin
– 90-day supply of Low Dose Naltrexone capsules
– A total of 30mL of Ultra Lipotropic 10

If Prescribed, Product Purchase Includes:
– Medication (3 components)
– Medical provider consultation
– Program guide
– Administration video

Administration and Frequency:

– As directed by your prescribing provider
– Sermorelin: subcutaneous injection, as directed
– LDN: oral capsule, as directed
– Ultra Lipotropic 10: subcutaneous injection, as directed
– Regular monitoring and follow-up with your prescribing provider are expected as part of this program

Contraindications

This program may not be appropriate for individuals who:
– Are currently using opioid medications of any kind. LDN is absolutely contraindicated with concurrent opioid use. Using LDN while taking opioids will precipitate acute opioid withdrawal. Disclose ALL current medications to your provider before starting.
– Have active cancer or a history of cancer. Sermorelin stimulates growth hormone secretion. Growth hormone may influence tumor growth. Patients with active malignancy or a history of cancer should not use Sermorelin without explicit oncology guidance.
– Have uncontrolled hypothyroidism. Sermorelin may not be effective in patients with hypothyroidism, and thyroid status should be optimized before starting. Discuss with your provider.
– Are pregnant or breastfeeding. Safety of all three components in pregnancy and breastfeeding has not been established. Do not use without explicit guidance from your independent licensed healthcare provider.
– Have known hypersensitivity to any component of the three formulations including naltrexone, sermorelin, methionine, inositol, choline, L-carnitine, or any B vitamin component.
– Have acute hepatitis or liver failure. Naltrexone is hepatically metabolized and is contraindicated in acute hepatitis or liver failure.

Warnings and Precautions

LDN – Opioid interaction (most critical):
Low Dose Naltrexone will block the effects of opioid medications and can precipitate acute opioid withdrawal in opioid-dependent patients. This is a medical emergency. This program must not be initiated by any patient currently using opioids including prescription opioid pain medications, opioid-based cough suppressants, or opioid use disorder treatments. Allow sufficient time for opioid clearance as directed by your provider before starting.

LDN – Surgical and procedural considerations:
If you have planned surgery, notify your surgeon and anesthesiologist that you are using LDN. Temporary discontinuation before procedures requiring opioid anesthesia will be necessary. Your prescribing provider will advise on timing.
Sermorelin – Growth hormone monitoring:
Sermorelin stimulates the pituitary gland to release growth hormone. Growth hormone levels should be monitored during treatment. Your provider will establish a monitoring schedule as part of the program.

Sermorelin – Fluid retention:
Growth hormone secretion can cause fluid retention, peripheral edema, and in some cases carpal tunnel symptoms. Report these to your provider promptly.

Liver function:
Naltrexone at standard doses has been associated with hepatotoxicity at high doses. Liver function should be monitored periodically. Patients with pre-existing liver conditions should discuss this with their provider.
Patients should inform their healthcare provider of ALL medical conditions, medications, and supplements prior to receiving this compounded program. This is especially critical given LDN's absolute contraindication with opioid medications.

Potential Side Effects
From Sermorelin:
– Injection site reactions (pain, redness, swelling)
– Water retention or peripheral edema
– Headache
– Flushing
– Dizziness
– Carpal tunnel symptoms with prolonged use
– Hyperglycemia (elevated blood sugar). Blood glucose monitoring may be appropriate
From Low Dose Naltrexone:
– Vivid dreams or sleep disturbances are commonly reported, particularly in the first few weeks
– Nausea; usually transient
– Headache
– Fatigue
– Anxiety; some patients report increased anxiety during the initial period
– Acute opioid withdrawal if opioids are present; see Warnings above
From Ultra Lipotropic 10:
– Injection site pain, redness, or bruising
– Nausea or gastrointestinal discomfort
– Fishy body odor (associated with choline metabolism in some individuals)
– Headache or dizziness

Seek immediate medical attention if you experience signs of acute opioid withdrawal (agitation, sweating, rapid heart rate, nausea/vomiting, severe anxiety), severe abdominal pain, or signs of a severe allergic reaction. Contact your prescribing provider promptly for any unexpected or concerning symptoms.